Holen Sie sich die Stockscreener-App
2.285
0.22%
0.005
Vorhandelsmarkt:
2.29
0.005
+0.22%
Schlusskurs vom Vortag:
$2.28
Offen:
$2.27
24-Stunden-Volumen:
226.20K
Relative Volume:
0.36
Marktkapitalisierung:
$128.74M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
228.50
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
-1.93%
1M Leistung:
-2.77%
6M Leistung:
-14.10%
1J Leistung:
+93.64%
1-Tages-Spanne:
$2.24
$2.325
1-Wochen-Bereich:
$2.18
$2.42
52-Wochen-Spanne:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.285 | 128.45M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Can Spero Therapeutics Inc. (2HA) stock test all time highsMarket Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Will Spero Therapeutics Inc. (2HA) stock benefit from sector leadership2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Why Spero Therapeutics Inc. stock is popular among millennials2025 Market Overview & Community Consensus Picks - Newser
How Spero Therapeutics Inc. (2HA) stock behaves in tightening cycles2025 Trading Recap & Intraday High Probability Alerts - Newser
How Spero Therapeutics Inc. stock benefits from global expansionStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
How Spero Therapeutics Inc. (2HA) stock performs during market turbulenceJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Published on: 2025-12-02 04:03:46 - Newser
Will Spero Therapeutics Inc. (2HA) stock remain on Wall Street radar2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Buy” at Wall Street Zen - Defense World
What analysts say about Spero Therapeutics Inc stockTop Performing Stocks & Market Trend Real-Time Reports - earlytimes.in
Can Silver Oak India Limited Maintain Its Share of Global Market for Its ProductStock Buy Signals & Get Free Training on Technical Indicators - earlytimes.in
Spero Therapeutics announces inducement grant under Nasdaq listing rule - TipRanks
Spero Therapeutics (SPRO) Awards New Employee with Restricted St - GuruFocus
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Breakout Move: Will Spero Therapeutics Inc. stock reach all time highs in 2025 - moha.gov.vn
Aug Mood: Will Spero Therapeutics Inc. stock reach all time highs in 2025July 2025 Patterns & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 200-Day Moving Average – Should You Sell? - Defense World
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight - The Globe and Mail
What is Spero Therapeutics Inc (SPRO) Stock Return on Shareholders’ Capital? - Setenews
Why Spero Therapeutics Inc. (2HA) stock is favored by hedge fundsJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Spero Therapeutics Inc. stock attract ESG investorsWeekly Trade Recap & Verified Swing Trading Watchlists - newser.com
How Spero Therapeutics Inc. (2HA) stock reacts to stronger dollarBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
What technical patterns form on Spero Therapeutics Inc. (2HA) stock chartsWeekly Profit Recap & AI Driven Price Forecasts - newser.com
Will Spero Therapeutics Inc. stock deliver strong dividend growth2025 Risk Factors & AI Forecasted Entry and Exit Points - newser.com
Will Spero Therapeutics Inc. benefit from macro trendsEntry Point & Safe Entry Zone Tips - newser.com
Published on: 2025-11-19 17:07:59 - newser.com
How Spero Therapeutics Inc. stock reacts to inflationary pressuresTrade Analysis Summary & Real-Time Price Movement Reports - newser.com
Published on: 2025-11-19 18:54:15 - newser.com
Why Spero Therapeutics Inc. stock is favored by pension fundsJuly 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
Will Spero Therapeutics Inc. stock pay special dividendsMarket Growth Summary & Real-Time Volume Trigger Notifications - newser.com
How Spero Therapeutics Inc. stock compares to industry benchmarks - newser.com
Spero Therapeutics: A High-Stakes Bet on a Single Drug - Ad-hoc-news.de
Is Spero Therapeutics Inc. (2HA) stock undervalued historicallyWeekly Market Report & Accurate Intraday Trading Signals - newser.com
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):